Objective: The present study was designed to investigate the integrated effects of the beta-1-selective blocker with vasodilator properties, nebivolol, on systemic haemodynamics, neurohormones and energy metabolism as well as oxygen uptake and exercise performance in physically active patients with moderate essential hypertension (EH). Design and methods: Eighteen physically active patients with moderate EH were included: age: 46.9 ؎ 2.38 years, weight: 83.9 ؎ 2.81 kg, blood pressure (BP): 155.8 ؎ 3.90/102.5 ؎ 1.86 mm Hg, heart rate: 73.6 ؎ 2.98 min −1 . After a 14-day wash-out period a bicycle spiroergometry until exhaustion (WHO) was performed followed by a 45-min submaximal exercise test on the 2.5 mmol/l lactate-level 48 h later. Before, during and directly after exercise testing blood samples were taken. An identical protocol was repeated after a 6-week treatment period with 5 mg nebivolol/day. Results: Nebivolol treatment resulted in a significant (P Ͻ 0.01) decrease in systolic and diastolic BP and heart
Introduction
Various prospective studies have shown that improvements in cardiovascular morbidity and mortality can be achieved by the cardiopulmonary, rate at rest and during maximal and submaximal exercise. Maximal physical work performance, blood lactate and rel. oxygen uptake (rel. VO 2 ) before and after nebivolol treatment at rest and during maximal and submaximal exercise remained unaltered. Free fatty acid, free glycerol, plasma catecholamines, beta-endorphines and atrial natriuretic peptide (ANP) increased before and after treatment during maximal and submaximal exercise but remained unaltered by nebivolol treatment. In contrast, plasma ANP levels at rest were significantly higher in the presence of nebivolol, endothelin-1 levels were unchanged. Conclusions: Nebivolol was effective in the control of BP at rest and during exercise in patients with EH. Furthermore, nebivolol did not negatively affect lipid and carbohydrate metabolism and substrate flow. The explanation for the effects on ANP at rest remain elusive. This pharmacodynamic profile of nebivolol is potentially suitable in physically active patients with EH.
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metabolic and humoral effects mediated by suitable forms of physical activity carried out at appropriate intensity, duration and frequency. [1] [2] [3] [4] On this basis, exercise therapy should play an important role in the management of cardiovascular disease. 5, 6 Particularly in the treatment of essential hypertension, physical exercise has become established as an effective therapeutic approach. [7] [8] [9] [10] Positive effects of controlled exercise programmes in hypertensive subjects have been reported to include a reduction in systolic and diastolic blood pressure, [11] [12] [13] improvements of blood lipid profile and insulin sensitivity of the working skeletal muscle, [14] [15] [16] [17] restoration of endothelial function, 18 a shift of the autonomic balance towards parasympathetic tone 19 and an improvement in quality of life. 20 However, if non-pharmacological measures alone fail to lower blood pressure to a normal level according to WHO/ISH guidelines, 21 additional antihypertensive drug treatment is necessary. Antihypertensive drug treatment should not only reduce major cardiovascular end points (myocardial infarction, sudden death, stroke) but also effectively control blood pressure at rest and during exercise without negative impact on physical performance and quality of life.
Nebivolol is a lipophilic beta-receptor blocker of the so called third-generation with distinct ␤-1 selective and vasodilating properties. 22, 23 A number of experimental and human pharmacological studies suggest that the vasodilatation is triggered via the endothelial nitrogen oxide system. The pharmacological profile is characterised by the significant antihypertensive effects as well as a lowering of cardiac pre-and after-load. 24 Up to now, however, there is still a lack of information about possible interactions of nebivolol with concomitant physical activity in patients with essential hypertension (EH). In this context, the effects of nebivolol on parameters of physical performance in connection with systemic haemodynamics, energy metabolism, lactate levels, oxygen uptake and subjective feeling of physical stress are of fundamental interest.
In this open, pilot study, therefore, effects of nebivolol on the above-mentioned parameters have been evaluated.
Patients, investigational design and methods
Eighteen physically active patients with mild primary hypertension (age: 46.9 Ϯ 2.38 years, weight: 83.9 Ϯ 2.81 kg, blood pressure: 155.8 Ϯ 3.90/102.5 Ϯ 1.86 mm Hg, heart rate: 73.6 Ϯ 2.98 min −1 mean duration of hypertension: 85.2 months) were included in the study. The antihypertensive medication was as follows: untreated (n = 13); angiotensin-converting enzyme (ACE)-inhibitor (n = 3), betablocker (n = 1), AT-1 antagonist (n = 1). Regular physical activity was defined as an exercise-related additional caloric requirement between 2000 and 2500 kilocalories (kcal) per week due to mostly dynamic exercise (eg, jogging, cycling or swimming). The type, duration and intensity of exercise was monitored by questionnaires combined with computed evaluation (own programmes, unpublished). Patients were eligible if they exhibited diastolic blood pressure values between 95 and 110 mm Hg on two different occasions during the 2-week run-in phase and if they were able to tolerate a workload of at least 75 Watts over a period of 3 min during the bicycle exercise test performed at the end of the run-in period. All subjects gave their informed consent in accordance with the Declaration of Helsinki. Ethics committee approval was obtained.
In order to exclude the presence of manifest cardiac, hepatic or renal disease, all patients had a physical examination performed, laboratory tests carried out and an ECG recorded.
At each visit, seated blood pressure was taken. After a 14-day wash-out period, a maximal bicycle exercise test (Siemens Erlangen, Germany, Type 380 bicycle ergometer) with concomitant spiroergometry (Oxycon Alpha Spiroergometry System by Jäger Wü rzburg, Germany) was performed in the sitting position. The spiroergometry was performed according to the WHO protocol (start: 25 Watts, 25 Watt increments at 2-min intervals), with tests carried out in the morning in an air-conditioned laboratory with uniform ambient air temperature and humidity ( Figure 1 ). The following parameters were determined: maximum work capacity, exercise-induced increase in blood pressure, perceived exertion (Borg scale), lactate, maximum oxygen uptake, carbohydrate and lipid metabolism as well as humoral factors.
In order to guarantee uniform caloric and fluid intake across all patients, patients were put on a standardised diet 24 h before study start. Moreover, patients were requested to abstain from alcohol, tea or coffee.
Forty-eight hours later, patients underwent a 45-min submaximal test at 5-min intervals. Workload was adjusted individually at an intensity corresponding to a lactate level of 2.5 mmol/l as determined before during maximal exercise test.
Lactate and glucose concentrations were determined in arterialised blood from the hyperaemic ear lobe. Prior to and after the exercise tests, venous blood was obtained from the cubital vein for the determination of the metabolic and neurohormonal parameters.
Subsequently, patients were treated with 5 mg nebivolol for a period of 42 days (one tablet a day at 8.00 am) and the exercise tests were repeated according to the same protocol at the end of the study. On ergometry days, dosing of nebivolol was postponed to after the exercise test in order to capture the trough effect.
Triglyceride, free fatty acid, glycerine, high-and low-density lipoprotein (HDL/LDL) cholesterol plasma levels were analysed by standard techniques; insulin, cortisol and human growth hormone (hGH) plasma levels were determined by use of enzyme immunoassay (System E. S. 300 Enzyme Test by Boehringer Mannheim, Germany). Beta endorphins were determined via radioimmunoassay (Nichols Institute, Wijchen, Holland). Plasma catecholamines were measured by HPLC (LKB, Bromma, Sweden).
The statistical analysis was performed with a repeated measurement ANOVA model with REML estimates (including exercise and treatment effects and their interactions). In case the assumption of normal distribution was rejected, log transformation was performed. All data were given as mean Ϯ s.e.m. (standard error of mean).
Results
A significant (P Ͻ 0.01) reduction in resting blood pressure was seen after a median of 42 days of nebivolol treatment: diastolic blood pressure from a mean of 102.5 Ϯ 1.86 to 91.9 Ϯ 1.40 mm Hg and systolic blood pressure from a mean of 155.8 Ϯ 3.90 to 132.8 Ϯ 3.82 mm Hg. This therapeutic effect was also seen with regard to the exercise-induced increase in blood pressure during each exercise level (Figure 2 ). Heart rate was significantly reduced at rest as well as at each level of exercise (Table 1 and Figure 3 ).
Absolute and relative oxygen uptake (rel. VO 2 ), lactate concentrations at the various levels of exer- cise before and after nebivolol treatment at rest and during maximal and submaximal exercise were not significantly altered by nebivolol treatment. Furthermore, no alteration of received perception of exertion (RPE) was observed under nebivolol treatment (Table 1 and Figure 3 ). Treatment with nebivolol did not induce any changes in maximal or submaximal work capacity relative to baseline. Maximal work capacity was 218.06 Ϯ 13.97 Watts prior to treatment with a lactate level of 7.70 Ϯ 0.51 mmol/l. During nebivolol (Table 1) . Free fatty acid, free glycerol, plasma adrenaline and beta-endorphins increased before and after treatment during maximal and submaximal exercise and were not significantly altered by nebivolol treatment (Tables 2 and 3) . Blood lipid profile is depicted in Table 4 . Total cholesterol and LDL-cholesterol before and after nebivolol treatment remained unchanged. In contrast, HDL-cholesterol was modestly but significantly reduced after nebivolol treatment, however the LDL/HDL quotient was unaltered. Nebivolol treatment did not significantly alter the exercise-induced effects on carbohydrate and lipid metabolism ( Table  2 ). In contrast, plasma ANP levels at rest were significantly higher in the presence of nebivolol, endothelin-1 levels remained unchanged (Table 3) . No relevant side effects developed during the treatment with nebivolol.
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Discussion
The present recommendations on treatment of essential hypertension are based on non-parmacological and pharmacological strategies, which are frequently applied simultaneously. Among the nonpharmacological treatment options regular dynamic physical activity at moderate intensities plays an important role. 10, 11 Thus, to ensure an effective and successful longterm exercise-therapy, potential effects of the antihypertensive medication on physical performance and on exercise-associated lipid and carbohydrate metabolism must also be considered.
This pilot study investigated the effects of the vasodilating beta-1 selective blocker, nebivolol, on physically active patients with mild essential hypertension without secondary complications. Physical activity was defined as a caloric expenditure of 2000-2500 kcal per week by exercise. Sports activities at this level mediate significant reductions in cardiovascular events and optimal adjustments of the cardiovascular risk profile including lipid and carbohydrate metabolism. 3, 5, 25 With respect to betablocking agents there is conflicting data on their suitability in the treatment of physically active patients with EH. The beneficial haemodynamic profile with marked antihypertensive effects during exercise may be counteracted by negative effects on lipid and carbohydrate metabolism as well as on exercise performance. 26, 27 Nebivolol is a third-generation beta-blocker. Previous studies have shown remarkable vasodilating effects with minimal alterations of the metabolic profile. 22, 23 However, there is little information available on its pharmacological effects in physically active hypertensive patients.
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This open pilot study, including a small but homogenous group of patients, was performed to obtain preliminary data on this important issue and to generate hypotheses for further blinded studies including larger numbers of patients. Taken these limitations into account the results of the present study demonstrate that treatment with nebivolol has a significant effect on resting blood pressure and on the exercise-induced increase in blood pressure during dynamic maximal muscular exercise. Heart rate was significantly decreased at rest and at all levels of exercise with nebivolol treatment.
Such a haemodynamic profile can be regarded as favourable for physically active patients, particularly given that premature vascular damage is considered to be attributable to excessive increases in blood pressure during exercise. 28 Furthermore, maximal and submaximal work capacity and perceived exertion were not compromised by the study drug treatment. This is of importance in view of strategies to implement long-term exercise programmes as a fundamental element in antihypertensive management.
The constellation of unaltered ET-1 and plasma adrenaline levels with significantly increased plasma atrial natriuretic peptide (ANP) levels at rest under nebivolol treatment is a potentially beneficial neurohumoral profile in the setting of essential hypertension. The functional significance of the increase in plasma concentrations of ANP, which has vasodilating properties, at rest remains elusive, however, and may not be further interpreted on the basis of the available data.
The observation of a significant increase of beta endorphin plasma levels during exercise with no alteration by nebivolol treatment is an important finding considering the positive effects of beta endorphins, both in the context of exercise tolerance and quality of life. 29, 30 The effects of antihypertensive therapy on the lipid and carbohydrate metabolism are relevant for long-term prognosis. 31 Nebivolol treatment did not alter the metabolic profile at rest or during exercise in a clinically relevant way. The modest decrease in HDL-cholesterol was compensated by the unaltered LDL/HDL quotient. Exercise-induced lipolysis plays a key role in energy metabolism. The fact that the FFA increase during exercise was not affected with nebivolol treatment suggests that the drug does not exert inhibitory effects on lipolysis.
The significant increases in insulin, cortisol and growth hormone plasma concentrations after exercise were not modified by nebivol treatment and are in accordance with previous findings in healthy, normotensive subjects undergoing the same exercise protocol. 32 Further evidence of the neutral effects of nebivolol on the various energy metabolism parameters comes from the observation of unaltered lactate dynamics during maximal exercise under treatment.
These effects on the metabolic profile are of bene-fit particularly for hypertensive patients with concomitant alterations of the lipid and carbohydrate metabolism. 12, 33 Neutral metabolic effects at rest and during exercise similar to those observed with nebivolol have been reported for ACE inhibitors, calcium channel antagonists and alpha-1-receptor blockers. 8 In contrast, some beta receptor blockers, especially those of the first and second generation, and diuretics, at least if administered at higher dose levels, are characterised by unfavourable effects on the metabolic profile. 34, 35 In summary, taking the limitations of an open label trial into account, monotherapy with the vasodilating ␤-1 selective beta-blocker nebivolol appears to be a suitable therapeutic option for physically active patients with mild-to-moderate essential hypertension. The pharmacological profile of nebivolol was characterised by effective blood pressure control at rest and during exercise in the presence of neutrality towards exercise-associated metabolism. Further controlled double-blind studies, however, are required to confirm the observed pharmacological profile of nebivolol in physically active hypertensive patients.
